1,832,007 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. purchased a new stake in 10x Genomics, Inc. (NASDAQ:TXG) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,832,007 shares of the company’s stock, valued at approximately $26,308,000. Assenagon Asset Management S.A. owned about 1.51% of 10x Genomics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in shares of 10x Genomics by 451.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock valued at $35,000 after purchasing an additional 1,265 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in 10x Genomics during the third quarter valued at $35,000. Blue Trust Inc. increased its holdings in 10x Genomics by 136.5% in the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after buying an additional 1,025 shares in the last quarter. Sound Income Strategies LLC purchased a new position in 10x Genomics in the third quarter valued at $46,000. Finally, Venturi Wealth Management LLC raised its position in shares of 10x Genomics by 1,108.9% in the third quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock worth $55,000 after acquiring an additional 2,240 shares during the period. 84.68% of the stock is owned by institutional investors and hedge funds.

10x Genomics Price Performance

TXG stock opened at $15.09 on Friday. 10x Genomics, Inc. has a 1 year low of $12.95 and a 1 year high of $51.22. The firm has a market capitalization of $1.83 billion, a PE ratio of -9.86 and a beta of 1.83. The business has a 50 day simple moving average of $14.99 and a 200-day simple moving average of $18.00.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.04. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The company had revenue of $151.65 million during the quarter, compared to analysts’ expectations of $158.84 million. During the same period in the prior year, the business earned ($0.51) EPS. The firm’s quarterly revenue was down 1.3% on a year-over-year basis. On average, equities research analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TXG. Canaccord Genuity Group cut their price target on 10x Genomics from $32.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, October 10th. The Goldman Sachs Group cut their price objective on 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research report on Wednesday, October 30th. Barclays decreased their target price on 10x Genomics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Stephens reissued an “overweight” rating and issued a $30.00 price target on shares of 10x Genomics in a report on Thursday, October 10th. Finally, Morgan Stanley decreased their price objective on shares of 10x Genomics from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, 10x Genomics presently has a consensus rating of “Moderate Buy” and an average price target of $23.86.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.